TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07583641: A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encepha

Sponsor: argenx · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07583641 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07583641 Rescue Dossier →